Bastien Vallée Marcotte1, Frédéric Guénard1, Simone Lemieux1, Patrick Couture1,2, Iwona Rudkowska2, Philip C Calder3,4, Anne Marie Minihane5, Marie-Claude Vohl1. 1. Institute of Nutrition and Functional Foods, Laval University, Quebec City, Quebec, Canada. 2. CHU de Québec Research Center-Endocrinology and Nephrology, Quebec City, Quebec, Canada. 3. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 4. NIHR Southampton Biomedical Research Center, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton, United Kingdom. 5. Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
Abstract
Background: Using a genome-wide association study (GWAS) approach, our group previously computed a genetic risk score (GRS) from single nucleotide polymorphisms (SNPs) of 10 loci that affect the plasma triglyceride (TG) response to an omega-3 (n-3) fatty acid (FA) supplementation. Objectives: The objective was to compute a novel and more refined GRS using fine mapping to include a large number of genetic variants. Methods: A total of 208 participants of the Fatty Acid Sensor (FAS) Study received 5 g fish oil/d, containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid, for 6 wk. Plasma TG concentrations were measured before and after supplementation. Dense genotyping and genotype imputation were used to refine mapping around GWAS hits. A GRS was computed by summing the number of at-risk alleles of tagging SNPs. Analyses were replicated in samples of the FINGEN study. Results: A total of 31 tagging SNPs associated with the TG response were used for GRS calculation in the FAS study. In a general linear model adjusted for age, sex, and body mass index, the GRS explained 49.73% of TG response variance (P < 0.0001). Nonresponders to the n-3 FA supplementation had a higher GRS than did responders. In the FINGEN replication study, the GRS explained 3.67% of TG response variance (P = 0.0006). Conclusions: Fine mapping proved to be effective to refine the previous GRS. Carrying increasing numbers of at-risk alleles of 31 SNPs confers a higher risk of being nonresponsive to n-3 FAs. The genetic profile therefore appears to be an important determinant of the plasma TG response to an n-3 FA supplementation and could be used to target those most likely to gain clinical benefit. This trial was registered at http://www.clinicaltrials.gov as NCT01343342.
Background: Using a genome-wide association study (GWAS) approach, our group previously computed a genetic risk score (GRS) from single nucleotide polymorphisms (SNPs) of 10 loci that affect the plasma triglyceride (TG) response to an omega-3 (n-3) fatty acid (FA) supplementation. Objectives: The objective was to compute a novel and more refined GRS using fine mapping to include a large number of genetic variants. Methods: A total of 208 participants of the Fatty Acid Sensor (FAS) Study received 5 g fish oil/d, containing 1.9-2.2 g eicosapentaenoic acid and 1.1 g docosahexanoic acid, for 6 wk. Plasma TG concentrations were measured before and after supplementation. Dense genotyping and genotype imputation were used to refine mapping around GWAS hits. A GRS was computed by summing the number of at-risk alleles of tagging SNPs. Analyses were replicated in samples of the FINGEN study. Results: A total of 31 tagging SNPs associated with the TG response were used for GRS calculation in the FAS study. In a general linear model adjusted for age, sex, and body mass index, the GRS explained 49.73% of TG response variance (P < 0.0001). Nonresponders to the n-3 FA supplementation had a higher GRS than did responders. In the FINGEN replication study, the GRS explained 3.67% of TG response variance (P = 0.0006). Conclusions: Fine mapping proved to be effective to refine the previous GRS. Carrying increasing numbers of at-risk alleles of 31 SNPs confers a higher risk of being nonresponsive to n-3 FAs. The genetic profile therefore appears to be an important determinant of the plasma TG response to an n-3 FA supplementation and could be used to target those most likely to gain clinical benefit. This trial was registered at http://www.clinicaltrials.gov as NCT01343342.
Authors: Iwona Rudkowska; Frédéric Guénard; Pierre Julien; Patrick Couture; Simone Lemieux; Olivier Barbier; Philip C Calder; Anne Marie Minihane; Marie-Claude Vohl Journal: J Lipid Res Date: 2014-05-19 Impact factor: 5.922
Authors: Evangelos C Rizos; Evangelia E Ntzani; Eftychia Bika; Michael S Kostapanos; Moses S Elisaf Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Jacqueline Madden; Christine M Williams; Philip C Calder; Georg Lietz; Elizabeth A Miles; Heather Cordell; John C Mathers; Anne Marie Minihane Journal: Annu Rev Nutr Date: 2011-08-21 Impact factor: 11.848
Authors: Anthony G Comuzzie; Shelley A Cole; Sandra L Laston; V Saroja Voruganti; Karin Haack; Richard A Gibbs; Nancy F Butte Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240
Authors: Luigi Barrea; Giuseppe Annunziata; Laura Bordoni; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano Journal: Int J Obes Suppl Date: 2020-07-20
Authors: Matthew Picklo; Bastien Vallée Marcotte; Michael Bukowski; Juan de Toro-Martín; Bret M Rust; Frédéric Guénard; Marie-Claude Vohl Journal: J Am Heart Assoc Date: 2021-01-19 Impact factor: 5.501